ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
1,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,5,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
2,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2,4,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
2,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2,6,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
2,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
3,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
3,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
3,3,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
3,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
4,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
4,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
5,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
6,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
6,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
6,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
7,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
7,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
8,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
8,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
9,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
9,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
10,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
10,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
11,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
12,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
13,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
13,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
14,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
14,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
15,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
15,2,Blood product transfusion dependent,Disability issues,Lifestyle issues,SocCi,N
15,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
15,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
16,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,3,Eosinophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
17,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
18,1,Concomitant disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
18,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
18,3,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,Y
19,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
20,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
21,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
21,2,Creatinine renal clearance,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
21,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
22,1,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
23,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
24,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
24,2,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
24,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
25,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
26,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
26,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
27,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
28,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
29,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
29,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
29,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
29,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
30,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
31,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
31,2,Headache,Headaches NEC,Headaches,Nerv,N
32,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
32,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
32,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
32,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
32,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
32,6,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
32,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
32,8,Metastases to heart,Metastases to specified sites,Metastases,Neopl,N
32,9,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
32,10,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
32,11,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
32,12,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
32,13,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
32,14,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
32,15,Right ventricular failure,Right ventricular failures,Heart failures,Card,N
33,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
33,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
33,3,Blood alkaline phosphatase decreased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
33,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
33,5,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
33,6,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
33,7,Blood urea decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
33,8,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
33,9,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
33,10,Eosinophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,11,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,12,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,13,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
33,14,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,15,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
33,16,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,17,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
33,18,Protein total decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
33,19,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
33,20,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
33,21,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
34,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
34,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
34,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
36,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
37,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
37,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
37,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
38,1,Duodenal ulcer,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
38,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
38,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
38,4,Small intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
39,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
39,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
40,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
40,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
40,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
40,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
40,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
41,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
41,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
41,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
41,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
42,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
42,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
43,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
43,2,Cheilitis,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
43,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
43,4,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
43,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
43,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
43,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
43,8,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
43,9,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
43,10,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
43,11,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
43,12,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
43,13,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
43,14,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
44,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
44,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
44,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
45,1,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
45,2,Metabolic disorder,Metabolic disorders NEC,Metabolism disorders NEC,Metab,N
45,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
45,4,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
45,5,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
46,1,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
46,2,Wound secretion,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
47,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
47,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
47,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
47,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
47,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
47,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
47,7,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
47,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
48,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
49,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
49,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
49,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
49,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
50,1,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
51,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
51,2,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
51,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
52,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
52,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
52,3,Lymphangitis,Vascular infections,Infections - pathogen unspecified,Infec,N
52,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
52,5,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
52,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
53,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
53,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
54,2,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
54,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
54,4,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
54,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
55,1,Adrenocortical carcinoma,Adrenal neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,Y
55,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
56,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
57,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
57,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
57,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
57,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
57,5,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
57,6,Urine analysis abnormal,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
58,1,Joint injury,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
58,2,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
58,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
59,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
59,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
60,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
61,1,Renal cell carcinoma recurrent,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
62,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
62,2,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
62,3,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
62,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
62,5,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
62,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
63,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
63,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
63,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
63,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
64,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
64,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
64,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
65,1,Renal function test abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
66,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
67,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
68,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
69,1,Clostridium difficile infection,Clostridia infections,Bacterial infectious disorders,Infec,N
69,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
70,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
71,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
72,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
73,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
74,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
75,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
75,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
75,3,Language disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
75,4,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
75,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
75,6,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
75,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
76,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
76,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
76,3,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
76,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
77,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
77,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
77,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
78,1,Dermatitis acneiform,Acnes,Skin appendage conditions,Skin,N
78,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
78,3,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
78,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
78,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
79,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
79,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
80,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
81,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
81,2,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
81,3,Panniculitis,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
81,4,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
82,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
83,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
83,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
83,3,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
84,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
85,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
86,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
87,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
87,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
87,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
87,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
88,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
89,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
90,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
90,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
90,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
90,4,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
90,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
90,6,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
90,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
90,8,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
91,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
91,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
92,1,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
92,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
92,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
93,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
94,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
94,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
94,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
94,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
94,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
95,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
95,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
95,3,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
95,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
96,1,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
97,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
98,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
98,2,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
98,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
98,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
98,5,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
99,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
100,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
100,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
100,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
100,4,Metastatic renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
100,5,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
101,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
102,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
103,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
103,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
103,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
103,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
103,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
103,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
103,7,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
103,8,Metastatic renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
103,9,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
103,10,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
103,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
103,12,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
104,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
105,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
106,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
106,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
107,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
107,2,Emphysema,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
107,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
108,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
108,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
108,3,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
108,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
108,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
108,6,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
108,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
108,8,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
108,9,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
108,10,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
109,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
110,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
110,2,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
110,3,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
111,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
112,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
113,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
113,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
113,3,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
113,4,Death,Death and sudden death,Fatal outcomes,Genrl,Y
113,5,Gastric haemorrhage,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
113,6,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
113,7,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
113,8,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
114,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
114,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
114,3,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
114,4,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
115,1,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
115,2,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,Y
115,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
116,1,Monoparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
116,2,Myelitis transverse,Myelitis (incl infective),Central nervous system infections and inflammations,Nerv,N
117,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
118,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
118,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
118,3,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
118,4,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
118,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
118,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
118,7,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
118,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
118,9,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
118,10,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
118,11,Metastases to thorax,Metastases to specified sites,Metastases,Neopl,N
118,12,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
118,13,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
118,14,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
118,15,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
119,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
119,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
119,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
119,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
119,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
120,1,Disease complication,General signs and symptoms NEC,General system disorders NEC,Genrl,N
120,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
120,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
121,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
121,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
121,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
122,1,Infectious mononucleosis,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
122,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
123,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
123,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
123,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
124,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
124,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
124,3,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,Y
124,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
125,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
125,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
125,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
125,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
125,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
125,6,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
125,7,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
125,8,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
126,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
126,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
126,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
126,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
127,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
127,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
127,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
128,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
128,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
129,1,Eating disorder,Eating disorders NEC,Eating disorders and disturbances,Psych,N
129,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
129,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
129,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
129,5,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
129,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
129,7,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
129,8,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
129,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
130,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
130,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
130,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
131,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
132,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,Y
132,2,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
132,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,Y
132,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
132,5,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
133,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
134,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
134,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
134,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
134,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
134,5,Metastatic renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
134,6,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
135,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
135,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
136,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
136,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
136,3,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
136,4,Blood pressure systolic decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
136,5,Blood sodium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
136,6,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
136,7,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
136,8,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
136,9,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
136,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
136,11,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
137,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
137,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
137,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
137,4,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
138,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
138,2,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
139,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
139,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
139,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
139,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
139,5,Metastatic renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,Y
139,6,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
139,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
140,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
140,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
140,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
141,1,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
141,2,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
142,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
142,2,Encephalitis herpes,Herpes viral infections,Viral infectious disorders,Infec,N
142,3,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
142,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
142,5,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
143,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
143,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
143,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
143,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
143,5,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
143,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
143,7,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
144,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
144,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
144,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
144,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
144,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
144,6,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
144,7,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
144,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
145,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
146,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
146,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
146,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
146,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
146,5,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
146,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
146,7,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
146,8,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
146,9,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
146,10,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
146,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
146,12,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
146,13,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
146,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
146,15,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
146,16,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
146,17,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
146,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
147,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
147,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
148,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
149,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
150,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
150,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
150,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
150,4,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
151,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
152,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
152,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
152,3,Circumoral oedema,Angioedemas,Angioedema and urticaria,Skin,N
152,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
152,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
152,6,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
152,7,Oropharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
152,8,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
152,9,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
153,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
153,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
153,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
153,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
153,5,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
153,6,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
154,1,Adrenocortical carcinoma,Adrenal neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
154,2,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
154,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
154,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
154,5,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
155,1,Adrenocortical carcinoma,Adrenal neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,Y
155,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
156,1,Adrenocortical carcinoma,Adrenal neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
156,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
156,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
156,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
156,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
157,1,Adrenocortical carcinoma,Adrenal neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,Y
157,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
157,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
158,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
159,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
159,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
159,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
159,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
159,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
159,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
159,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
160,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
160,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
160,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
161,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
161,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
161,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
162,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
162,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
162,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
162,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
162,5,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
162,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
162,7,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
162,8,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
162,9,Mean cell volume decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
162,10,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
162,11,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
162,12,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
163,1,"Astrocytoma, low grade",Gliomas benign,Nervous system neoplasms benign,Neopl,N
163,2,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
163,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
164,1,Encephalitis viral,Viral infections NEC,Viral infectious disorders,Infec,N
164,2,Personality disorder,Personality disorders NEC,Personality disorders and disturbances in behaviour,Psych,N
164,3,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
165,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
165,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
166,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
166,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
167,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
168,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
168,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
168,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
168,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
168,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
169,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
169,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
169,3,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
169,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
170,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
170,2,Dermatitis infected,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
170,3,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
170,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
171,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
171,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
172,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
173,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
174,1,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
174,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
174,3,Tetany,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
175,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
176,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
176,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
176,3,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
177,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
177,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
177,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
178,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
178,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
178,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
179,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
179,2,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
180,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
180,2,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
180,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
180,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
181,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
182,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
183,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
183,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
183,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
183,4,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
183,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
183,6,Headache,Headaches NEC,Headaches,Nerv,N
183,7,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
183,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
183,9,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
183,10,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
183,11,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
183,12,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
183,13,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
183,14,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
183,15,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
183,16,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
183,17,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
183,18,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
184,1,Acne,Acnes,Skin appendage conditions,Skin,N
184,2,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
184,3,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
184,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
184,5,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
184,6,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
184,7,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
184,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
184,9,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
184,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
185,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
185,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
185,3,Oral herpes,Herpes viral infections,Viral infectious disorders,Infec,N
185,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
185,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
186,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
186,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
186,3,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
186,4,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
186,5,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
186,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
186,7,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
186,8,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
186,9,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
186,10,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
186,11,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
186,12,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
186,13,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
186,14,Respiratory tract irritation,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
186,15,Tongue discomfort,Tongue signs and symptoms,Tongue conditions,Gastr,N
186,16,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
187,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
187,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
187,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
187,4,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
187,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
187,6,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
187,7,Migraine,Migraine headaches,Headaches,Nerv,N
187,8,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
187,9,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
188,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
189,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
189,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
189,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
189,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
189,5,Headache,Headaches NEC,Headaches,Nerv,N
189,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
189,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
189,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
189,9,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
189,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
190,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
190,2,Acne,Acnes,Skin appendage conditions,Skin,N
190,3,Appendicitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
190,4,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
190,5,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
190,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
190,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
190,8,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
190,9,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
190,10,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
190,11,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
190,12,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
190,13,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
190,14,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
190,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
190,16,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
190,17,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
191,1,Acne,Acnes,Skin appendage conditions,Skin,N
191,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
191,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
191,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
191,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
191,6,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
191,7,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
191,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
191,9,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
191,10,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
191,11,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
191,12,Inflammation,Inflammations,General system disorders NEC,Genrl,N
191,13,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
191,14,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
191,15,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
191,16,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
191,17,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
191,18,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
191,19,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
191,20,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
191,21,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
191,22,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
191,23,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
191,24,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
191,25,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
191,26,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
191,27,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
192,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
192,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
192,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
192,4,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
192,5,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
192,6,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
192,7,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
192,8,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
192,9,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
192,11,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
192,12,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
192,13,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
192,14,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
192,15,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
192,16,Headache,Headaches NEC,Headaches,Nerv,N
192,17,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
192,18,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
192,19,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
192,20,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
192,21,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
192,22,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
192,23,Metastases to skin,Metastases to specified sites,Metastases,Neopl,N
192,24,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
192,25,Nail bed infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
192,26,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
192,27,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
192,28,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
192,29,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
192,30,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
192,31,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
192,32,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
192,33,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
192,34,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
192,35,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
192,36,Synovial cyst,Synovial disorders,Synovial and bursal disorders,Musc,N
192,37,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
192,38,Tooth discolouration,Dental surface disorders,Dental and gingival conditions,Gastr,N
192,39,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
192,40,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
192,41,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
193,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
193,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
193,3,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
193,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
193,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
193,6,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
193,7,Headache,Headaches NEC,Headaches,Nerv,N
193,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
193,9,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
193,10,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
193,11,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
193,12,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
193,13,Onychoclasis,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
193,14,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
193,15,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
193,16,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
193,17,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
193,18,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
193,19,Rhinalgia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
193,20,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
193,21,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
193,22,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
193,23,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
194,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
195,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
195,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,4,Hypercalcaemia of malignancy,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
195,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
195,6,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
196,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
196,2,Blood creatine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
196,3,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
196,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
196,5,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
196,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
196,7,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
196,8,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
196,9,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
196,10,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
197,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
197,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
197,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
197,4,Stridor,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
197,5,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
198,1,Duodenal ulcer perforation,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
199,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
199,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
199,3,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
199,4,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
199,5,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
199,6,Sensation of foreign body,Feelings and sensations NEC,General system disorders NEC,Genrl,N
199,7,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
199,8,Upper airway obstruction,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
199,9,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
200,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
201,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
202,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
202,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
202,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
202,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
202,5,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
202,6,Intestinal mass,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
202,7,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
202,8,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
202,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
202,10,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
202,11,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
202,12,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
203,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
203,2,Acne cystic,Acnes,Skin appendage conditions,Skin,N
203,3,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
203,4,Autonomic neuropathy,Autonomic nervous system disorders,Neuromuscular disorders,Nerv,N
203,5,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
203,6,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
203,7,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
203,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
203,9,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
203,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
203,11,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
203,12,Initial insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
203,13,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
203,14,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
203,15,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
203,16,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
203,17,Urinary hesitation,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
204,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
205,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
205,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
206,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
207,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
207,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
208,1,Creatinine renal clearance increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
208,2,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
208,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
208,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
209,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
210,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
210,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
211,1,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
211,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
211,3,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
211,4,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
211,5,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
211,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
211,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
211,8,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
212,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
212,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
213,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
214,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
214,2,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
214,3,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
215,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
215,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
216,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
216,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
217,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
217,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
217,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
217,4,Oropharyngeal spasm,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
217,5,Papule,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
217,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
217,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
217,8,Type I hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
217,9,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
218,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
219,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
219,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
220,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
220,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
220,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
221,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
221,2,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,Y
221,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
221,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
221,5,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
221,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
221,7,Urine output decreased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
222,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
222,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
222,3,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
223,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
224,1,Eyelid oedema,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
225,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
225,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
225,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
225,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
226,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
227,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
227,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
227,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
228,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
228,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
228,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
229,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
229,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
229,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
229,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
229,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
230,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
230,2,Laryngospasm,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
231,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
231,2,Metastases to pleura,Metastases to specified sites,Metastases,Neopl,N
232,1,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
233,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
233,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
234,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
235,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
236,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
236,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
236,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
236,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
236,5,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
236,6,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
236,7,Renal cancer metastatic,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,Y
236,8,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
236,9,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
237,1,Immunosuppression,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
237,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
238,1,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
238,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
238,3,Meningeal disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
238,4,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
238,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
238,6,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
239,1,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
239,2,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
240,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
241,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
242,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
243,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
244,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
244,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
244,3,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
245,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
245,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
245,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
246,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
246,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
246,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
246,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
247,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
248,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
249,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
250,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
250,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
250,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
250,4,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
250,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
251,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
251,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
251,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
252,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
253,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
254,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
254,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
254,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
254,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
254,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
254,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
254,7,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
254,8,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
254,9,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
255,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
255,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
255,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
256,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
256,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
257,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
257,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
258,1,Granulomatous liver disease,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
258,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
258,3,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
258,4,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
258,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
258,6,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
259,1,Cardiac failure acute,Heart failures NEC,Heart failures,Card,N
259,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
259,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
259,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
259,5,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
259,6,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
260,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
260,2,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
261,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
261,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
262,1,Granulomatous liver disease,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
262,2,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
262,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
262,4,Splenic lesion,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
262,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
262,6,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
263,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
263,2,Epstein-Barr virus antibody positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
263,3,Parvovirus B19 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
264,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
265,1,Blood bicarbonate increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
265,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
265,3,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
265,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
265,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
266,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
266,2,Gastroenteritis norovirus,Caliciviral infections,Viral infectious disorders,Infec,Y
267,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
267,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
267,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
267,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
267,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
268,1,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
268,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
268,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
268,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
268,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
268,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
268,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
269,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
269,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
269,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
269,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
269,5,Freezing phenomenon,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
269,6,Hepatic cancer metastatic,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
269,7,Lung cancer metastatic,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
269,8,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
269,9,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
269,10,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
269,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
270,1,Corneal epithelial microcysts,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
270,2,Corneal striae,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
270,3,Iridocyclitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
270,4,Iris adhesions,"Iris and ciliary body structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
270,5,Vitritis,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
271,1,Pulmonary toxicity,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
272,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
273,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
274,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
275,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
276,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
277,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
277,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
277,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
277,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
278,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
279,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
279,2,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
280,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
280,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
280,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
280,4,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
280,5,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
280,6,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
280,7,Tooth infection,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
281,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
281,2,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
282,1,Bradyphrenia,Thinking disturbances,Disturbances in thinking and perception,Psych,N
282,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
282,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
282,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
283,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
283,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
284,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
284,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
284,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
285,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
286,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
286,2,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
287,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
288,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
288,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
289,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
289,2,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
289,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
290,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
290,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
290,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
290,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
290,5,Left ventricular failure,Left ventricular failures,Heart failures,Card,N
290,6,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
291,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
291,2,Learning disorder,Learning disorders,Cognitive and attention disorders and disturbances,Psych,N
291,3,Tibia fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
292,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
292,2,Atelectasis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
292,3,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
292,4,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
292,5,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
292,6,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
292,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
292,8,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
292,9,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
292,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
292,11,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
292,12,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
292,13,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
292,14,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
292,15,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
292,16,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
292,17,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
292,18,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
292,19,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
292,20,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
292,21,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,Y
292,22,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
292,23,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
292,24,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
292,25,Tachypnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
293,1,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
293,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
294,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
294,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
294,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
295,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
295,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
295,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
296,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
296,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
296,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
296,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
296,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
297,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
297,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
297,3,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
298,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
298,2,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
299,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
299,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
299,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
300,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
300,2,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
301,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
301,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
301,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
301,4,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
301,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
301,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
302,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
302,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
302,3,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
302,4,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
303,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
303,2,Anuria,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
303,3,Complications of transplanted kidney,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
303,4,Graft haemorrhage,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
303,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
303,6,Kidney rupture,Renal and urinary tract injuries NEC,Injuries NEC,Inj&P,N
303,7,Kidney transplant rejection,Transplant rejections,Immune disorders NEC,Immun,N
303,8,Retroperitoneal haematoma,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
304,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
305,1,Bronchial disorder,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
305,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
305,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
305,4,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
305,5,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
305,6,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
305,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
305,8,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
305,9,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
306,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
306,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
307,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
308,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
308,2,Neurotoxicity,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
308,3,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
308,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
308,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
309,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
309,2,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
310,1,Atelectasis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
310,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
310,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
310,4,Crepitations,General signs and symptoms NEC,General system disorders NEC,Genrl,N
310,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
310,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
310,7,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
310,8,Emphysema,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
310,9,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
310,10,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
310,11,Lung opacity,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
310,12,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
310,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
310,14,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
310,15,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
310,16,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
310,17,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
310,18,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
311,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
312,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
312,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
312,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
312,4,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
313,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
314,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,Y
314,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
315,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
316,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
317,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
317,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
317,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
317,4,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
317,5,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
317,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
318,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
319,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
319,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
319,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
320,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
320,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
321,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
321,2,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
321,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
321,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
321,5,Lymphadenopathy mediastinal,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
321,6,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
321,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
321,8,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
322,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
323,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
324,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
324,2,Headache,Headaches NEC,Headaches,Nerv,N
325,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
326,1,Appendicitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
327,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
327,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
327,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
328,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
328,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
328,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
328,4,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
328,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
328,6,Empyema,Infections NEC,Infections - pathogen unspecified,Infec,N
328,7,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
328,8,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
328,9,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
328,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
328,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
328,12,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
329,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
329,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
329,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
329,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
329,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
329,6,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
329,7,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
329,8,Sputum discoloured,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
330,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
330,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
330,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
330,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
330,5,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
331,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
331,2,Enteritis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
331,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
332,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
332,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
332,3,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
332,4,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
333,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
333,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
333,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
333,4,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
334,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
334,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
335,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
335,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
335,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
335,4,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
335,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
335,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
335,7,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
335,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
335,9,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
335,10,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
335,11,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
335,12,Pathological fracture,Fractures NEC,Fractures,Musc,N
335,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
335,14,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
336,1,Acute generalised exanthematous pustulosis,Pustular conditions,Epidermal and dermal conditions,Skin,N
337,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
338,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
338,2,Cardiomegaly,Myocardial disorders NEC,Myocardial disorders,Card,N
338,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
338,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
338,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
338,6,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
338,7,Neutrophilia,Leukocytoses NEC,White blood cell disorders,Blood,N
338,8,Pericardial disease,Pericardial disorders NEC,Pericardial disorders,Card,N
338,9,Pleural thickening,Pleural conditions NEC,Pleural disorders,Resp,N
338,10,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
339,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
340,1,Back disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
340,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
340,3,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
340,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
341,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
341,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
341,3,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
341,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
341,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
341,6,Sputum discoloured,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
342,1,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
342,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
342,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
342,4,Renal haemorrhage,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
342,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
343,1,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
344,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
344,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
345,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
345,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
345,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
345,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
345,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
346,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
347,1,Pneumocystis jirovecii infection,Pneumocystis infections,Fungal infectious disorders,Infec,N
348,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
348,2,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
349,1,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
350,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
351,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
352,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
353,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
354,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
354,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
355,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
355,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
355,3,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
355,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
356,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
356,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
357,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
357,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
358,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
358,2,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
358,3,Headache,Headaches NEC,Headaches,Nerv,N
358,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
358,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
358,6,Migraine,Migraine headaches,Headaches,Nerv,N
358,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
358,8,Tongue ulceration,Tongue disorders,Tongue conditions,Gastr,N
359,1,Acute lung injury,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
359,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
360,1,Acute interstitial pneumonitis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
360,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
360,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
360,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
361,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
361,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
361,3,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
361,4,Protein urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
361,5,Urine albumin/creatinine ratio increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
361,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
362,1,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
363,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
363,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
363,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
364,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
364,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
365,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
366,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
367,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
367,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
367,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
367,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
368,1,Acne,Acnes,Skin appendage conditions,Skin,N
369,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
369,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
369,3,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
370,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
370,2,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
371,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
371,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
372,1,Angiomyolipoma,Soft tissue neoplasms benign NEC,Soft tissue neoplasms benign,Neopl,N
372,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
372,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
372,4,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
373,1,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
374,1,Blood chloride increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
374,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
374,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
374,4,Headache,Headaches NEC,Headaches,Nerv,N
374,5,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
374,6,Mean cell haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
374,7,Mean cell volume decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
374,8,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
374,9,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
374,10,Protein urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
374,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
374,12,Red blood cell count increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
374,13,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
374,14,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
375,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
375,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
375,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
375,4,Blood chloride increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
375,5,Blood test abnormal,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
375,6,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
375,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
375,8,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
375,9,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
375,10,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
375,11,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
375,12,Protein urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
375,13,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
375,14,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
375,15,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
375,16,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
375,17,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
375,18,Urine protein/creatinine ratio increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
376,1,Drug level decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
376,2,Lip dry,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
376,3,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
376,4,Seizure cluster,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
376,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
377,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
378,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
378,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
378,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
378,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
378,5,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
378,6,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
378,7,Sjogren's syndrome,Connective tissue disorders NEC,Connective tissue disorders (excl congenital),Musc,N
379,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
379,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
379,3,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
379,4,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
380,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
381,1,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
382,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
382,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
382,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
382,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
382,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
382,6,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
382,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
382,8,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
382,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
383,1,5-hydroxyindolacetic acid increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
383,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
383,3,Blood gastrin increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
383,4,Bone loss,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
383,5,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
383,6,Borderline ovarian tumour,Female reproductive neoplasms unspecified malignancy,Reproductive neoplasms female malignant and unspecified,Neopl,N
383,7,Bronchial carcinoma,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
383,8,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
383,9,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
383,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
383,11,Hyperplasia,Trophic disorders,Tissue disorders NEC,Genrl,N
383,12,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
383,13,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
383,14,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
383,15,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
383,16,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
383,17,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
383,18,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
383,19,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
383,20,Pelvic mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
383,21,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
383,22,Pulmonary hilum mass,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
383,23,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
383,24,Spinal pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
383,25,Thyroid disorder,Thyroid disorders NEC,Thyroid gland disorders,Endo,N
383,26,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
384,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
384,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
384,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
384,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
384,5,Spinal pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
385,1,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
386,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
386,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
386,3,Organising pneumonia,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
387,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
387,2,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
387,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
387,4,Pneumococcal sepsis,Streptococcal infections,Bacterial infectious disorders,Infec,N
387,5,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
388,1,Blood creatinine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
388,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
388,3,Mean cell volume increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
388,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
388,5,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
389,1,Atypical pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
389,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
389,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
389,4,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
390,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
391,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
391,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
392,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
392,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
392,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
392,4,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
392,5,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
392,6,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
392,7,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
392,8,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
392,9,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
393,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
393,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
393,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
393,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
393,5,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
393,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
393,7,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
393,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
393,9,Productive cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
393,10,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
394,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
394,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
394,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
395,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
396,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
396,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
396,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
396,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
396,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
396,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
396,7,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
396,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
397,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
397,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
397,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
398,1,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
399,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
400,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
400,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
401,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
401,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
401,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
402,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
402,2,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
402,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
402,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
402,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
402,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
402,7,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
402,8,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
402,9,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
402,10,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
402,11,Seizure cluster,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
402,12,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
403,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
403,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
403,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
403,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
403,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
404,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
405,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
405,2,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
405,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
405,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
405,5,Seizure cluster,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
406,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
406,2,Blood chromogranin A increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
406,3,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
406,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
406,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
406,6,Parathyroid hormone-related protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
406,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
407,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
407,2,Bleeding varicose vein,Varicose veins NEC,Venous varices,Vasc,N
407,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
407,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
407,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
407,6,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
407,7,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
407,8,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
407,9,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
408,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
409,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
409,2,Partial seizures,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
409,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
409,4,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
410,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
410,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
411,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
412,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
412,2,Seizure cluster,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
413,1,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
414,1,Acne,Acnes,Skin appendage conditions,Skin,N
414,2,"Astrocytoma, low grade",Gliomas benign,Nervous system neoplasms benign,Neopl,N
414,3,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
414,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
414,5,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
414,6,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
414,7,Spinal cord injury,Spinal cord injuries NEC,Injuries NEC,Inj&P,N
414,8,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
415,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
415,2,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
415,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
416,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
417,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
417,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
418,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
418,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
419,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
420,1,Abnormal behaviour,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
420,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
420,3,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
420,4,Exposure to contaminated water,Non-occupational environmental exposures,"Exposures, chemical injuries and poisoning",Inj&P,N
420,5,Immune system disorder,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
420,6,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
420,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
421,1,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
421,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
421,3,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
422,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
422,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
422,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
423,1,Exposed bone in jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
423,2,Fistula,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
423,3,Gingival pain,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
423,4,Loose tooth,Dental disorders NEC,Dental and gingival conditions,Gastr,N
423,5,Osteonecrosis of jaw,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
423,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
423,7,Periodontal disease,Dental disorders NEC,Dental and gingival conditions,Gastr,N
423,8,Purulence,Infections NEC,Infections - pathogen unspecified,Infec,N
423,9,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
424,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
425,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
425,2,Partial seizures,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
426,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
426,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
427,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
427,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
427,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
427,4,Menstrual disorder,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
427,5,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
427,6,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
427,7,Sputum purulent,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
428,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
428,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
428,3,Inflammatory marker increased,Chemistry analyses NEC,Protein and chemistry analyses NEC,Inv,N
428,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
428,5,Menstrual disorder,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
428,6,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
428,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
428,8,Nitrite urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
428,9,Sputum purulent,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
429,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
430,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
430,2,Generalised onset non-motor seizure,Absence seizures,Seizures (incl subtypes),Nerv,N
430,3,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
430,4,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
431,1,Cellulitis of male external genital organ,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
431,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
432,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
433,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
433,2,Atelectasis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
433,3,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
433,4,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
433,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
433,6,Metapneumovirus infection,Viral infections NEC,Viral infectious disorders,Infec,N
433,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
433,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
434,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
434,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
434,3,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
435,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
436,1,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
436,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
436,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
437,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
438,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
439,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
440,1,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
440,2,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
440,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
441,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
441,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
442,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
442,2,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
443,1,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
443,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
443,3,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
443,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
443,5,Pharyngeal ulceration,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
444,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
444,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
445,1,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
446,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
446,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
446,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
446,4,Mediastinal disorder,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
446,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
446,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
446,7,PIK3CA-activated mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
446,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
447,1,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
448,1,Cervix cancer metastatic,Cervix neoplasms malignant,Reproductive neoplasms female malignant and unspecified,Neopl,N
448,2,Cervix haemorrhage uterine,Cervix disorders NEC,Cervix disorders (excl infections and inflammations),Repro,N
448,3,Endometrial cancer metastatic,Endometrial neoplasms malignant,Reproductive neoplasms female malignant and unspecified,Neopl,N
448,4,Invasive lobular breast carcinoma,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
448,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
448,6,Metastases to gastrointestinal tract,Metastases to specified sites,Metastases,Neopl,N
448,7,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
448,8,Metastases to ovary,Metastases to specified sites,Metastases,Neopl,N
448,9,Metastases to retroperitoneum,Metastases to specified sites,Metastases,Neopl,N
449,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
449,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
450,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
451,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
452,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
453,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
454,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
455,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
456,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
457,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
458,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
459,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
460,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
461,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
462,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
462,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
462,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
462,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
463,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
463,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
464,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
465,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
466,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
466,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
466,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
466,4,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
467,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
467,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
468,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
468,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
469,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
469,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
469,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
470,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
471,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
471,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
472,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
472,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
473,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
473,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
474,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
475,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
475,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
476,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
476,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
477,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
478,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
479,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
479,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
480,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
481,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
482,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
483,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
484,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
485,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
486,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
486,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
487,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
488,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
489,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
489,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
489,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
489,4,PIK3CA-activated mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
490,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
490,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
491,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
491,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
492,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
493,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
494,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
495,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
496,1,Drug level therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
497,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
498,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
499,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
499,2,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
500,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
501,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
501,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
502,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
503,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
504,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
505,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
506,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,Y
507,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
507,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
508,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
509,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
510,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
511,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
511,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
512,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
513,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
514,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
515,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
516,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
517,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
518,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
518,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
519,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
520,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
521,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
522,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
523,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
524,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
524,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
525,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
526,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
527,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
528,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
528,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
529,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
530,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
531,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
532,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
532,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
533,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
534,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
535,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
536,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
537,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
538,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
539,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
540,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
541,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
542,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
543,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
544,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
544,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
545,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
545,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
546,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
546,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
546,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
547,1,Abdominal lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
547,2,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
547,3,Carcinoid tumour pulmonary,Carcinoid tumours,Endocrine neoplasms malignant and unspecified,Neopl,N
547,4,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
547,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
547,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
547,7,Pleural neoplasm,Respiratory tract and pleural neoplasms malignancy unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
547,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
548,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
548,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
549,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
550,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
550,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
551,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
552,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
553,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
554,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
554,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
555,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
556,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
557,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
557,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
558,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
559,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
560,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
561,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
562,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
563,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
564,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
565,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
566,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
567,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
568,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
569,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
570,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
571,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
572,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
572,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
573,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
574,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
575,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
575,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
576,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
577,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
578,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
579,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
579,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
579,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
579,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
580,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
580,2,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
580,3,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
580,4,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
580,5,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
580,6,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
580,7,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
580,8,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
580,9,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
580,10,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
580,11,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
580,12,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
580,13,Blood triglycerides increased,Triglyceride analyses,Lipid analyses,Inv,N
580,14,Brain stem glioma,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
580,15,Brain stem glioma,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
580,16,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
580,17,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
580,18,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
580,19,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
580,20,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
580,21,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
580,22,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
580,23,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
580,24,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
580,25,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
580,26,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
580,27,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
580,28,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
580,29,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
580,30,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
580,31,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
580,32,Myoclonus,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
580,33,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
580,34,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
580,35,Ocular hyperaemia,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
580,36,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
580,37,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
580,38,Reflux gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
580,39,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
580,40,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
581,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
582,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
583,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
583,2,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
583,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
584,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
584,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
584,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
585,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
586,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
587,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
587,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
588,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
588,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
589,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
590,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
591,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
592,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
593,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
594,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
595,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
596,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
597,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
597,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
598,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
598,2,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
598,3,Bone lesion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
598,4,Invasive lobular breast carcinoma,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
598,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
598,6,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
598,7,Uterine mass,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
599,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
600,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
601,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
602,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
603,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
604,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
605,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
606,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
607,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
608,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
609,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
610,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
611,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
612,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
612,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
613,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
614,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
614,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
615,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
616,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
617,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
618,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
618,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
619,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
620,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
621,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
622,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
623,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
623,2,Drug level therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
624,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
625,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
625,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
626,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
626,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
627,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
628,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
629,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
630,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
631,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
631,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
632,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
632,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
633,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
634,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
635,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
636,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
637,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
638,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
639,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
640,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
640,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
640,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
641,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
641,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
642,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
643,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
644,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
645,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
646,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
646,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
646,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
646,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
646,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
646,6,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
647,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
647,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
648,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
649,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
650,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
650,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
650,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
651,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
652,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
653,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
654,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
655,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
656,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
657,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
658,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
659,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
660,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
661,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
662,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
663,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
664,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
664,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
665,1,Anal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
665,2,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
665,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
665,4,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
665,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
665,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
665,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
665,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
665,9,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
666,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
667,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
668,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
668,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
669,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
670,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
671,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
672,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
672,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
673,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
674,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
675,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
676,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
677,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
678,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
679,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
680,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
681,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
681,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
681,3,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
682,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
683,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
684,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
685,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
686,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
687,1,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
688,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
689,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
689,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
689,3,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
689,4,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
689,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
689,6,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
689,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
689,8,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
689,9,Metastases to breast,Metastases to specified sites,Metastases,Neopl,N
689,10,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
689,11,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
689,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
689,13,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
689,14,Vaginal discharge,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
690,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
691,1,Hypercholesterolaemia,Elevated cholesterol,Lipid metabolism disorders,Metab,N
692,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
693,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
694,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
695,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
696,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
697,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
698,1,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
699,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
700,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
700,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
700,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
701,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
702,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
703,1,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
703,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
704,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
704,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
705,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
706,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
706,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
706,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
707,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
708,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
709,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
710,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
711,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
712,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
713,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
713,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
714,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
714,2,Lymphangioleiomyomatosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
714,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
714,4,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
715,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
716,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
717,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
717,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
717,3,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
718,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
718,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
719,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
719,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
720,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
721,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
722,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
722,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
723,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
724,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
724,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
725,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
725,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
726,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
727,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
728,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
729,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
730,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
731,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
732,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
733,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
734,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
734,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
735,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
736,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
737,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
738,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
738,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
739,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
740,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
741,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
742,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
742,2,Immune system disorder,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
743,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
744,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
745,1,Eye oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
746,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
747,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
748,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
748,2,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
749,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
749,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
749,3,Brain stem glioma,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
749,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
749,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
749,6,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
750,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
750,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
751,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
751,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
752,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
753,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
754,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
755,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
756,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
757,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
758,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
759,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
759,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
760,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
761,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
762,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
763,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
764,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
765,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
766,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
767,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
768,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
768,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
769,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
770,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
771,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
772,1,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
773,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
774,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
775,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
775,2,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
775,3,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
776,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
777,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
777,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
778,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
779,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
780,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
780,2,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
780,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
780,4,Death,Death and sudden death,Fatal outcomes,Genrl,Y
780,5,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
780,6,Dysphonia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
780,7,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
780,8,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
780,9,Lymphatic fistula,Lymphangiopathies,Lymphatic vessel disorders,Vasc,N
780,10,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
780,11,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
780,12,Mucosal inflammation,Mucosal findings abnormal,General system disorders NEC,Genrl,N
780,13,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
780,14,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
780,15,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
781,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
782,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
783,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
784,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
784,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
785,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
786,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
787,1,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
788,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
789,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
789,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
790,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
791,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
792,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
793,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
794,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
795,1,Blood creatine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
795,2,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
795,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
795,4,Nephropathy toxic,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
795,5,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
796,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
797,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
798,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
799,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
800,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
801,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
802,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
802,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
803,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
803,2,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
804,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
805,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
805,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
806,1,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
807,1,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
808,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
809,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
810,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
810,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
811,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
812,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
813,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
814,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
815,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
816,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
816,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
816,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
817,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
817,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
818,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
818,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
819,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
820,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
821,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
822,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
823,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
824,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
825,1,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
826,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
826,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
827,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
827,2,Headache,Headaches NEC,Headaches,Nerv,N
827,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
827,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
827,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
827,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
827,7,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
827,8,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
827,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
828,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
828,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
828,3,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
828,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
828,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,7,Liver abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
828,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
828,9,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
828,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
828,11,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
828,12,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
828,13,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
828,14,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
829,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
829,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
829,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
830,1,Brain stem glioma,Glial tumours malignant,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
830,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
830,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
830,4,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
830,5,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
830,6,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
830,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
831,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
831,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
831,3,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
831,4,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
831,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
831,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
831,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
831,8,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
831,9,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
831,10,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
831,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
831,12,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
831,13,Palmar-plantar erythrodysaesthesia syndrome,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
831,14,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
831,15,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
831,16,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
831,17,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
831,18,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
832,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
832,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
833,1,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
834,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
835,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
836,1,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
837,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
838,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
839,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
840,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
841,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
842,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
843,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
844,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
844,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
845,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
846,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
847,1,Drug level above therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
847,2,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
848,1,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
849,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
849,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
849,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
849,4,Insulinoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
849,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
849,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
849,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
850,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
850,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
851,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
852,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
853,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
854,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
855,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
856,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
857,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
858,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
859,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
860,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
860,2,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
860,3,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
860,4,Oral infection,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
860,5,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
860,6,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
861,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
861,2,Diabetes insipidus,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
861,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
861,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
862,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
863,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
864,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
865,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
866,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
867,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
868,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
869,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
870,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
870,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
871,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
872,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
872,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
873,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
874,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
874,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
874,3,Renal cell carcinoma,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
875,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
876,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
877,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
877,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
878,1,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
878,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
878,3,Product shape issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
878,4,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
879,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
880,1,Activated partial thromboplastin time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
880,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
880,3,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
880,4,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
880,5,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
